Aller au contenu principal
xMedica

NCT07606066ClinicalTrials.gov

A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies

En recrutementAccepte des participants actuellement, selon la fiche du registre.
Contacter cette étude

En bref

The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient…

Observationnelle2 150 participants recherchés76 sites7 pays

Catégories

Enregistré dans 1 registre

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 20 days after the recorded start)First posted 2026-05-26; recorded start 2026-05-06
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
  • Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
  • Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1019 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Masking not stated in the record

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 71 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 2,150 participants (target), run at 76 sites, across 7 countries.

How this score is built
  • Enrolment33/40

    2,150 participants (target)

  • Site count21/25

    71 sites

  • Country count12/15

    7 countries

  • Planned duration5/10

    Planned over about 11 months

  • Sponsor scale10/10

    AstraZeneca has led 991 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical regions.

Affections

  • Type 2 Diabetes

Éligibilité

Éligibilité
SexeTous
Âges18 YearsAucun maximum
Volontaires sainsNon
Méthode d'échantillonnageNON_PROBABILITY_SAMPLE

Population de l'étude

Adults with Type 2 Diabetes

Éligibilité telle qu'elle figure dans le registre

Inclusion Criteria: * Participants must be ≥ 18 years of age at the time of signing the ICF. * Patients with a diagnosis of T2DM, test- or documentation-confirmed as per World Health Organization or local diagnostic standards, inadequately managed with: 1. Lifestyle management alone, AND/OR 2. A stable dose of background glucose-lowering medication(s) for T2DM (As specified in the Protocol) for at least 45 days prior to signing the ICF. * Expresses interest in participating in an ongoing or future T2DM clinical study, is motivated and willing to make themselves available for the duration of the study, and is able to follow study procedures as required. * Provision of signed and dated written informed consent (As specified in the Protocol) before any study-specific procedures, sampling, or analysis. Exclusion Criteria: * Current or planned use of GLP-1 RAs prohibited in ongoing or future T2DM studies evaluating the efficacy and safety of investigational GLP-1 RAs (As specified in the Protocol). * Diagnosed with Type 1 diabetes mellitus. * Known pregnancy at the time of visit or having the intention to become pregnant.

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étudeObservationnelle
PhaseNon précisé dans la fiche du registre
RépartitionNon précisé dans la fiche du registre
Modèle d'interventionNon précisé dans la fiche du registre
Objectif principalNon précisé dans la fiche du registre
InsuNon précisé dans la fiche du registre
Recrutement2 150 participants recherchés

Promoteur et collaborateurs

  • AstraZeneca Promoteur

Groupes et interventions

  • Participants with Type 2 Diabetes

    Participants with Type 2 Diabetes

Interventions

  • Autre Procedure: assessment

    The approximate volume of blood required is 2 mL

Critères de jugement

  1. Critère de jugement principal

    Patient demographics

    Summary statistics

    Délai Visit 1 (Single day)

  2. Critère de jugement principal

    Medical and surgical history

    Summary statistics

    Délai Visit 1 (Single day)

  3. Critère de jugement principal

    Concomitant medication

    Summary statistics

    Délai Visit 1 (Single day)

  4. Critère de jugement principal

    HbA1c levels

    Summary statistics

    Délai Visit 1 (Single day)

  5. Critère de jugement secondaire

    Referral to ongoing or future T2DM study.

    Number of participants with high likelihood of meeting eligibility criteria in ongoing or future T2DM studies, for referral to those studies.

    Délai Visit 1 (Single day)

Dates

Dates
Date de début6 mai 2026 (réelle)
Achèvement principal31 mars 2027 (estimée)
Achèvement31 mars 2027 (estimée)
Première publication26 mai 2026 (réelle)
Dernière mise à jour25 août 2026
Résultats publiésNon précisé dans la fiche du registre
Statut vérifié pour la dernière foismars 2026

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

19 sites sont en recrutement

Brazil

Brazil
ÉtablissementVilleÉtat ou régionStatut
Research SiteBarretosPas encore en recrutement
Research SiteBrasíliaPas encore en recrutement
Research SiteCampinasSão PauloPas encore en recrutement
Research SiteCuritibaParanáEn recrutement
Research SiteFortalezaCearáPas encore en recrutement
Research SiteNatalRio Grande do NortePas encore en recrutement
Research SitePorto AlegreRio Grande do SulPas encore en recrutement
Research SiteRio de JaneiroPas encore en recrutement
Research SiteSão José dos CamposSão PauloPas encore en recrutement
Research SiteSão PauloSão PauloPas encore en recrutement
Research SiteSão PauloSão PauloPas encore en recrutement

Hungary

Hungary
ÉtablissementVilleÉtat ou régionStatut
Research SiteBudapestEn recrutement
Research SiteBudapestPas encore en recrutement
Research SiteBudapestEn recrutement
Research SiteBudapestHUEn recrutement
Research SiteBudapestHUEn recrutement
Research SiteDebrecenHUPas encore en recrutement
Research SiteSalgótarjánPas encore en recrutement
Research SiteSzegedHUPas encore en recrutement
Research SiteSzolnokPas encore en recrutement
Research SiteZalaegerszegEn recrutement

India

India
ÉtablissementVilleÉtat ou régionStatut
Research SiteBangaloreKarnatakaPas encore en recrutement
Research SiteBelagaviKarnatakaPas encore en recrutement
Research SiteBelagaviKarnatakaPas encore en recrutement
Research SiteCalicutKeralaPas encore en recrutement
Research SiteChennaiTamil NaduPas encore en recrutement
Research SiteCoimbatoreTamil NaduPas encore en recrutement
Research SiteDelhiNew DelhiPas encore en recrutement
Research SiteGunturAndhra PradeshPas encore en recrutement
Research SiteGuwahatiAssamPas encore en recrutement
Research SiteIndoreMadhya PradeshPas encore en recrutement
Research SiteJaipurRajasthanPas encore en recrutement
Research SiteKochiKeralaPas encore en recrutement
Research SiteKolkataWest BengalPas encore en recrutement
Research SiteLucknowUttar PradeshPas encore en recrutement
Research SiteMumbaiMaharashtraPas encore en recrutement
Research SiteNagpurMaharashtraPas encore en recrutement
Research SitePuneMaharashtraPas encore en recrutement
Research SitePuneMaharashtraPas encore en recrutement
Research SiteThiruvananthapuramKeralaPas encore en recrutement

Malaysia

Malaysia
ÉtablissementVilleÉtat ou régionStatut
Research SiteBatu CavesSelangorRetiré
Research SiteKuala LumpurWilayah Persekutuan Kuala LumpPas encore en recrutement
Research SitePutrajayaPas encore en recrutement
Research SiteSerembanNegeri SembilanEn recrutement
Research SiteSeri ManjungPerakPas encore en recrutement

Poland

Poland
ÉtablissementVilleÉtat ou régionStatut
Research SiteBialystokPodlaskie VoivodeshipEn recrutement
Research SiteCzęstochowaSilesian VoivodeshipPas encore en recrutement
Research SiteKielceŚwiętokrzyskie VoivodeshipPas encore en recrutement
Research SiteKrakowMalopolskaPas encore en recrutement
Research SiteLodzŁódź VoivodeshipEn recrutement

26 sites supplémentaires sont indiqués dans la fiche du registre.

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

  1. 25 août 2026

    Site ajouté

    5 sites added (76 total)

    7176